Novartis, CH0012005267

Novartis stock: Rhapsido data extend efficacy through week 52

Published on 11/14/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock drew attention after new clinical results for Rhapsido. The FDA is reviewing tumor risks linked to Zolgensma while retaining a favorable benefit-risk view.

Novartis advances pipeline focus

Novartis reported sustained Rhapsido responses in chronic inducible urticaria on November 12.
The FDA said on November 6 that Zolgensma and Itvisma face a malignancy risk review while their benefits continue to outweigh potential risks.
Novartis presented longer-term ianalumab results in Sjogren's disease on November 10.

Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis highlighted new clinical and regulatory developments during the week of November 9-13, 2026. On November 12, the company announced 52-week results from the Phase III RemIND program for Rhapsido (remibrutinib) in chronic inducible urticaria. The Novartis press release said responses remained sustained through Week 52 and that additional regulatory submissions for chronic inducible urticaria are planned.

Pipeline updates shape the week

On November 10, Novartis presented longer-term ianalumab results from the NEPTUNUS extension study at the American College of Rheumatology Convergence. The company said disease activity and several reported outcomes continued to improve, with no new safety findings. Ianalumab is under regulatory review in several countries, including the United States.

Regulatory risk also remained in focus. In a notice dated November 6, the Food and Drug Administration said it had received reports of malignancies in patients treated with Zolgensma and was assessing whether regulatory action was appropriate. The agency also said the benefits of Zolgensma and Itvisma continue to outweigh their potential risks for approved uses.

Novartis stock traded at 145.51 euros on Lang & Schwarz at 11:39 CET on Saturday, November 14.